HIM
CPRX

Hillsdale Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hillsdale Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-243,500
Closed -$4.8M – 671
2025
Q3 		$4.8M Sell
243,500
-21,300
-8% -$438K 0.14% 203
2025
Q2 		$5.75M Buy
264,800
+67,700
+34% +$1.6M 0.21% 118
2025
Q1 		$4.78M Buy
197,100
+7,100
+4% +$160K 0.24% 73
2024
Q4 		$3.97M Buy
190,000
+100
+0.1% +$2.15K 0.2% 133
2024
Q3 		$3.78M Buy
+189,900
New +$3.52M 0.29% 137
2024
Q1 		– Sell
-280
Closed -$4.71K – 606
2023
Q4 		$4.71K Sell
280
-80
-22% -$1.09K ﹤0.01% 541
2023
Q3 		$4.21K Sell
360
-254,960
-100% -$3.41M ﹤0.01% 544
2023
Q2 		$3.43M Sell
255,320
-80,580
-24% -$1.16M 0.32% 135
2023
Q1 		$5.57M Sell
335,900
-23,900
-7% -$394K 0.48% 64
2022
Q4 		$6.69M Sell
359,800
-121,900
-25% -$1.88M 0.57% 32
2022
Q3 		$6.18M Sell
481,700
-173,900
-27% -$2.06M 0.56% 39
2022
Q2 		$4.59M Buy
655,600
+5,700
+0.9% +$41.8K 0.37% 95
2022
Q1 		$5.39M Buy
+649,900
New +$4.59M 0.35% 93
2018
Q1 		– Sell
-17,000
Closed -$66K – 482
2017
Q4 		$66K Buy
+17,000
New +$56.2K 0.01% 307

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hillsdale Investment Management's CPRX Position: Q4 2025 in Review

Hillsdale Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 243,500 shares — an estimated $4.8M sold.

Hillsdale Investment Management first reported a position in CPRX in Q4 2017 and held it in 14 quarters. The position peaked at $6.69M in Q4 2022. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Hillsdale Investment Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 243,500 Catalyst Pharmaceutical shares in Q4 2025, an estimated $4.8M.
  • Hillsdale Investment Management first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 14 quarters.
  • Hillsdale Investment Management's Catalyst Pharmaceutical position peaked at $6.69M in Q4 2022.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Hillsdale Investment Management's 13F filing for Q4 2025, filed 10 Feb 2026.